|
Protocol Number:
03-H-0192
- Title:
Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-back for Hematological Malignancies - Effect of Irradiated Donor Lymphocytes on Chimerism
- Number:
03-H-0192
- Summary:
Bone marrow transplantation (BMT) is a risky procedure. If doctors could reduce the complications, BMT would be safer to use for a wider range of conditions. The purposes of this study are
- to prevent graft rejection by increasing the amount of immunosuppression and by giving some lymphocytes from the donor before transplant;
- to prevent graft-versus-host disease (GVHD) by transplanting T-cell depleted stem cells;
- to improve the immune effect against residual leukemia by the add-back of donor lymphocytes before transplant and six or more weeks after transplant.
Beyond the standard BMT protocol, study participants will undergo additional procedures. First, along with total body irradiation, patients will receive two drugs (a high dose of cyclophosphamide and fludarabine) to suppress immunity and prevent rejection of the transplant. Second, four days before the transplant, patients will be given donor lymphocytes that have been irradiated to make them incapable of causing GVHD. On the day of the transplant, patients will receive an infusion of T-cell depleted bone marrow stem cells. Finally, patients will receive two doses of add-back donor T-cells (45 and 100 days post transplant) and the immunosuppressive drug cyclosporine starting on day 44 until about six months after transplant.
Study participants must be between the ages of 10 and 56 and have a family member who is a suitable stem cell donor match.
- Sponsoring Institute:
-
National Heart, Lung and Blood Institute (NHLBI)
- Recruitment Detail
- Type:
Completed Study; data analyses ongoing
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
None
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Currently Not Provided
- Keyword(s):
-
Chronic Myelogenous Leukemia
-
Acute Lymphoblastic Leukemia
-
Acute Myelogenous Leukemia (AML)
-
Chronic Lymphocytic Leukemia
-
Myelodysplastic Syndrome
-
Non-Hodgkin's Lymphoma
-
Graft-versus Leukemia/Myeloma
-
Graft-versus-host Disease
-
Cyclosporine
-
Fludarabine
- Recruitment Keyword(s):
-
Chronic Myelogenous Leukemia
-
Acute Lymphoblastic Leukemia
-
Acute Myelogenous Leukemia (AML)
-
Chronic Lymphocytic Leukemia
-
Myelodysplasia Syndrome
-
Non-Hodgkin's Lymphoma
- Condition(s):
-
Acute Lymphocytic Leukemia
-
Chronic Myeloid Leukemia
-
Acute Myelocytic Leukemia
-
Myelodysplastic Syndromes
-
Myeloproliferative Disorders
- Investigational Drug(s):
- None
- Investigational Device(s):
-
Isolex 300i Stem Cell Selection
- Interventions:
-
Device: Isolex 300i Stem Cell Selection
- Supporting Site:
-
National Heart, Lung and Blood Institute
- Contact(s):
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citation(s):
-
Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant. 1996 Aug;18(2):347-53.
-
Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996 Oct 15;88(8):3223-9.
-
Mavroudis DA, Read EJ, Molldrem J, Raptis A, Plante M, Carter CS, Phang S, Dunbar CE, Barrett AJ. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant. 1998 Mar;21(5):431-40.
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/16/2008
|
|